Results 141 to 150 of about 278,985 (182)
Some of the next articles are maybe not open access.
Dopamine agonists in schizophrenia: a review
European Neuropsychopharmacology, 1995Although it is unlikely that the different types of course and severity of schizophrenia are caused by one neurochemical abnormality alone, indirect pharmacological evidence still suggests a relative excess of dopaminergic activity being implicated in the pathogenesis of most of the schizophrenic symptoms, e.g. positive symptomatology.
O, Benkert +2 more
openaire +2 more sources
Alopecia induced by dopamine agonists
Neurology, 2002We report two women with PD who developed alopecia while being treated with the dopamine agonists pramipexole and ropinirole. The alopecia reversed partially after the drugs were discontinued. Both women were postmenopausal and had no history of hair loss or other dermatologic disorders.
Rowena E, Tabamo, Alessandro, Di Rocco
openaire +2 more sources
Ropinirole hydrochloride, a dopamine agonist
Acta Crystallographica Section C Crystal Structure Communications, 2006Ropinirole hydrochloride, or diethyl[2-(2-oxo-2,3-dihydro-1H-indol-4-yl)ethyl]ammonium chloride, C16H25N2O+.Cl-, belongs to a class of new non-ergoline dopamine agonists which bind specifically to D2-like receptors with a selectivity similar to that of dopamine (D3 > D2 > D4).
Krishnan, Ravikumar +1 more
openaire +2 more sources
Switching and combining of dopamine agonists
Journal of Neurology, 2004Dopamine agonists have been proved safe and effective as initial therapy in early stages of Parkinson's disease. Prospective long-term clinical trials demonstrated that initial symptomatic treatment with a dopamine agonist is associated with a significantly reduced risk for motor complications in comparison with levodopa therapy.
Susann, Junghanns +2 more
openaire +2 more sources
Dopamine agonists and Parkinson's disease
Clinical Neurology and Neurosurgery, 1984The therapeutic use of dopamine agonists for Parkinson's disease, clinical guidelines for their introduction into antiparkinson regimens, and their range of adverse effects are reviewed. The role played by the dopaminomimetic ergots in elucidating dopamine receptor function, and laboratory methods that identify dopamine agonists, are also examined.
K, Burton, D B, Calne
openaire +2 more sources
Partial dopamine agonists in schizophrenia
British Journal of Hospital Medicine, 2005The emergence of partial dopamine agonists reinforces the argument for the dopamine hypothesis of schizophrenia. Aripiprazole (Abilify®) is the first of these compounds for the treatment of schizophrenia to be launched in the UK. Aripiprazole has a promising efficacy and favourable tolerability profile that suggests it has a significant role to play in
openaire +2 more sources
Dopamine agonists for cocaine dependence
2003Cocaine is a major drug of abuse. Cocaine dependence is a common and serious condition, which has become nowadays a substantial public health problem. There is a wide and well documented range of consequences associated to chronic use of this drug, such as medical, psychological and social problems, including the spread of infectious diseases (e.g ...
B G O, Soares +3 more
openaire +3 more sources
Clinical Pharmacology of Dopamine Agonists
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2000With the availability of newer dopamine agonists selective for dopamine (D 2 ) receptor subtypes, medical management of Parkinson's disease has progressed substantially. These agents can decrease the frequency of ergot‐related side effects and dyskinesias.
openaire +2 more sources